BioNTech SE ADR closed $17.54 below its 52-week high ($131.49), which the company achieved on September 17th.

The ADR's fall snapped a three-day winning streak.

BioNTech SE ( (BNTX) ) has provided an update. BioNTech SE has settled a dispute with the National Institutes of Health (NIH) regarding royalties allegedly owed on sales of its COVID-19 vaccine, ...

BioNTech SE has reached a settlement agreement with the University of Pennsylvania over a royalty dispute related to its COVID-19 vaccine, developed in collaboration with Pfizer. The agreement ...

BioNTech SE (NASDAQ:BNTX – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the seventeen ...

Tidal Investments LLC lessened its stake in BioNTech SE (NASDAQ:BNTX – Free Report) by 39.5% in the third quarter, according ...

Concurrently, the company has amended its license agreements to provide for a low single-digit percentage royalty on Net Sales of Licensed Products for 2024 onwards. Currently, BioNTech's stock is ...

Analyst Akash Tewari from Jefferies maintained a Buy rating on BioNTech SE (BNTX – Research Report) and keeping the price target at ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Investing in biotech stocks usually isn't for the faint of heart. These stocks tend to be highly volatile because of the ...

Dec 13 (Reuters) - BioNTech SE (22UAy.DE), opens new tab said on Friday it has been informed by its partner OncoC4 that the U ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...